NewAmsterdam Pharma News

EnGene Announces the Election of Paul Hastings and Wouter Joustra to Its Board of Directors

Business Wire04:05

NewAmsterdam Pharma (NAMS.US) was first covered by TD Cowen, giving it a buy rating.

NewAmsterdam Pharma (NAMS.US) was first covered by TD Cowen, giving it a buy rating.

Zhitong Finance01:21

TD Cowen Initiates Coverage On NewAmsterdam Pharma With Buy Rating

TD Cowen analyst Tyler Van Buren initiates coverage on NewAmsterdam Pharma with a Buy rating.

Analyst Upgrades01:12

NewAmsterdam Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 — TD Cowen Initiates Coverage On → Buy 03/14/2024 73.81% Scotiabank → $35 Initiates Coverage O

Benzinga01:11

Strong Buy Rating for NewAmsterdam Pharma on Obicetrapib's Promising Efficacy and Market Potential

TipRanksMay 15 18:32

NewAmsterdam Pharma Company (NAMS) Receives a Buy From Scotiabank

TipRanksMay 10 20:12

NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0.51) YoY

First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily

BenzingaMay 9 21:04

Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M

08:04 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M

MT NewswiresMay 9 20:04

NewAmsterdam Pharma 1Q Rev $1.4M >NAMS

NewAmsterdam Pharma 1Q Rev $1.4M >NAMS

Dow JonesMay 9 20:01

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Pha

Dow JonesMay 9 20:00

10-Q: Quarterly report

Futu NewsMay 9 04:39 · Announcements

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients

GlobeNewswireMay 4 04:01

12 Health Care Stocks Moving In Monday's After-Market Session

GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings

BenzingaApr 30 04:31

Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), NewAmsterdam Pharma Company (NAMS) and Humana (HUM)

TipRanksApr 29 20:09

NewAmsterdam Pharma (NAMS.US) Announces Phase 2 Trial Results of CETP Inhibitor Under Development Effectively Reduces “Bad Cholesterol” Levels

Recently, NewAmsterdam Pharma (NAMS.US) announced the results of its phase 2 trial of the CETP inhibitor obiceTrapib at the American College of Cardiology (ACC) in 2024. Analysis showed that obicetrapib, as a single drug or in combination with ezetimibe, can effectively reduce low density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia (dyslipidemia). NewAmsterdam also announced that Prevail for its related Phase 3 key trial has reached recruitment9

Zhitong FinanceApr 10 11:29

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients With Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS） today announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial ("CVOT") evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease ("ASCVD"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

GlobeNewswireApr 9 20:00

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)

TipRanksApr 2 20:30

NewAmsterdam Pharma Names Juliette Audet Chief Business Officer

NewAmsterdam Pharma (NAMS) said Monday that Juliette Audet has been named chief business officer and has resigned from the company's board, effective immediately. Audet most recently served as a partn

MT NewswiresApr 1 21:56

NewAmsterdam Pharma Announces Executive Leadership Changes

TipRanksApr 1 20:32

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

We are privileged to welcome Juliette to our management team as CBO," said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.

GlobeNewswireApr 1 20:00